IL115451A0 - Use of a serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine - Google Patents

Use of a serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine

Info

Publication number
IL115451A0
IL115451A0 IL11545195A IL11545195A IL115451A0 IL 115451 A0 IL115451 A0 IL 115451A0 IL 11545195 A IL11545195 A IL 11545195A IL 11545195 A IL11545195 A IL 11545195A IL 115451 A0 IL115451 A0 IL 115451A0
Authority
IL
Israel
Prior art keywords
prevention
treatment
combination
receptor antagonist
migraine
Prior art date
Application number
IL11545195A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL115451A0 publication Critical patent/IL115451A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL11545195A 1994-10-05 1995-09-28 Use of a serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine IL115451A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/318,391 US5744482A (en) 1994-10-05 1994-10-05 Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine

Publications (1)

Publication Number Publication Date
IL115451A0 true IL115451A0 (en) 1995-09-28

Family

ID=23237987

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11545195A IL115451A0 (en) 1994-10-05 1995-09-28 Use of a serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine

Country Status (12)

Country Link
US (1) US5744482A (de)
EP (1) EP0710479B1 (de)
AT (1) ATE175347T1 (de)
AU (1) AU4130196A (de)
DE (1) DE69507112T2 (de)
DK (1) DK0710479T3 (de)
ES (1) ES2125567T3 (de)
GR (1) GR3029666T3 (de)
IL (1) IL115451A0 (de)
SI (1) SI0710479T1 (de)
WO (1) WO1996011000A1 (de)
ZA (1) ZA958173B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020028798A1 (en) * 1995-12-12 2002-03-07 Omeros Medical Systems Irrigation solution and method for inhibition of pain and inflammation
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US6492332B1 (en) 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
WO1996019233A2 (en) * 1994-12-12 1996-06-27 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
US20040127884A1 (en) * 1994-12-12 2004-07-01 Omeros Corporation Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis
WO1996041633A1 (en) * 1995-06-08 1996-12-27 Eli Lilly And Company Methods of treating cold and allergic rhinitis
US6413961B1 (en) * 1995-12-12 2002-07-02 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
BR9509985A (pt) 1995-12-12 1998-11-03 Omeros Med Sys Inc Solução para irrigação e método para inibição de dor inflamação e esparmo
AU4074897A (en) * 1996-09-18 1998-04-14 Eli Lilly And Company A method for the prevention of migraine
GB9620777D0 (en) * 1996-10-07 1996-11-20 Merck Sharp & Dohme Therapeutic use
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
DE19917347A1 (de) * 1999-04-16 2000-11-09 Gsf Forschungszentrum Umwelt Verfahren und Vorrichtung zum trockenen Anbringen von Substanzen an inhalierbare pulverförmige Trägerstoffe
CA2324116A1 (en) * 1999-10-25 2001-04-25 Susan Beth Sobolov-Jaynes Nk-1 receptor antagonists and eletriptan for the treatment of migraine
AUPQ514600A0 (en) * 2000-01-18 2000-02-10 James Cook University Brain injury treatment
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
AU2002351412B2 (en) 2001-12-21 2010-05-20 Exelixis Patent Company Llc Modulators of LXR
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
US20070065463A1 (en) * 2003-06-20 2007-03-22 Ronald Aung-Din Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions
US20050282879A1 (en) * 2004-06-17 2005-12-22 Foad Salehani Methods and composition for treatment of migraine and symptoms thereof
WO2007070504A2 (en) * 2005-12-13 2007-06-21 Morton Grove Pharmaceuticals, Inc. Stable and palatable oral liquid sumatriptan compositions
JP2010538985A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 抗ｈｉｖ剤としての副甲状腺ホルモン（１−３４）の使用

Also Published As

Publication number Publication date
DE69507112T2 (de) 1999-06-10
GR3029666T3 (en) 1999-06-30
DE69507112D1 (de) 1999-02-18
DK0710479T3 (da) 1999-08-30
AU4130196A (en) 1996-05-02
EP0710479A1 (de) 1996-05-08
US5744482A (en) 1998-04-28
SI0710479T1 (en) 1999-06-30
WO1996011000A1 (en) 1996-04-18
EP0710479B1 (de) 1999-01-07
ES2125567T3 (es) 1999-03-01
ATE175347T1 (de) 1999-01-15
ZA958173B (en) 1997-04-01

Similar Documents

Publication Publication Date Title
ZA958173B (en) Use of a serotonin agoinist in combination with a tachykinin receptor antaonist in the treatment or prevention of migraine
DE69734006D1 (de) Verfahren zur erleichterung von schmerzen durch eine kombination von tramadol und einen nmda-antagonist
AP2001002129A0 (en) 5HT1 receptor agonists and metoclopramide for the treatment of migrane.
IL142921A0 (en) USES FOR Eph RECEPTOR ANTAGONISTS AND AGONISTS TO TREAT VASCULAR DISORDERS
AP2002002642A0 (en) A phamaceutical composition for treatment of acute, chronic pain and/ or neuropathic pain and migraines
EP1186304A3 (de) Pharmazeutische Kombinationen zur Behandlung von Schlaganfälle und traumatischen Gehirnschäden
BR0106462A (pt) Composições farmacêuticas para distúrbios do snc e outros distúrbios
BR0200283A (pt) Composições farmacêuticas para o tratamento de distúrbios do snc e de outros distúrbios
NO2013017I2 (no) (a)dekstrometorfan eller et farmasøytisk akseptabelt salt derav, for eksempel dekstrometorfanhydrobromid og (b) quinidin eller etfarmasøytisk akseptabelt salt derav, for eksempel quinidinsulfat
EP0715855A3 (de) NK-1 Rezeptor Antagonisten und 5HT3 Rezeptor Antagonisten zur Behandlung von Emesis
NZ334029A (en) Use of serotonin 5-HT1F agonist for the treatment of common colds or allergic rhinitis
MX9700030A (es) Administracion de pirenzipina, matilescopolamina y otros antagonistas del receptor mascurinico para el tratamiento de transtornos del metabolismo de lipidos.
BR9811780A (pt) Método de aumento de volume ósseo usando agonistas seletivos fp não ocorrendo naturalmente
EP0832650A3 (de) Verwendung von Serotonin 5-HT1F Agonisten zur Vorbeugung der Migräne
EP1064966A3 (de) Zusammensetzungen von 5HT1-Rezeptor -Antagonisten, Koffein und COX-2 Inhibitoren zur Behandlung von Migräne
WO2001045684A3 (en) Formulations of adenosine a1 agonists
ZA972601B (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
WO2000006082A3 (en) Treatment of anxiety disorders
EP1064948A3 (de) Zusammensetzungen von 5HT1-Rezeptor -Antagonisten, Koffein und COX-2 Inhibitoren zur Behandlung von Migräne
EP0797994A3 (de) Verwendung eines oder mehrerer 5-HT-2 Rezeptor-Antagonisten zur Herstellung eines Wirkstoffs für die Behandlung der Symptome von giftigen Bissen oder Stichen
BR9907896A (pt) "combinação de um antagÈnico alfa-adrenérgico e de um agente doador de óxido de nitrogênio para o tratamento de disfunções sexuais femininas"
EP1051994A3 (de) 5HT1-Rezeptor-Agonisten und COX-2 Inhibitoren zur Behandlung von Migräne
WO2001045682A3 (en) Formulations of adenosine a1 agonists
EP1508337A3 (de) Verwendung von Eph-Rezeptor-Antangonisten und Agonisten zur Behandlung von vaskulären Krankheiten
WO2001045686A3 (en) Formulations of adenosine a1 agonists